Ropeginterferon alfa-2b

Drug Profile

Ropeginterferon alfa-2b

Alternative Names: AOP-2014; P-1101; Peg-IFN-alpha-2b; PEG-P-IFN-alpha-2b; Pegylated proline interferon-alfa-2b

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmaEssentia Corporation
  • Developer AOP Orphan Pharmaceuticals AG; Institute of Liver and Biliary Sciences; Mayo Clinic; National Cancer Institute (USA); PharmaEssentia Corporation
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols; Small molecules
  • Mechanism of Action Interferon alpha 2b stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Polycythaemia vera
  • Phase III Essential thrombocythaemia; Hepatitis B
  • Phase II Chronic myeloid leukaemia; Hepatitis C; Myelofibrosis
  • Preclinical Cancer

Most Recent Events

  • 25 Jun 2017 Updated efficacy and adverse events data from the PROUD-PV, PEN-PV and PEGINVERA trials in Polycythemia Vera presented at the 22nd Congress of the European Hematology Association (EHA-2017)
  • 04 May 2017 Phase-II clinical trials in Chronic myeloid leukaemia (Second-line therapy or greater) in Germany (SC)
  • 25 Apr 2017 Clinical trials in Hepatitis B (Treatment-experienced) in India (SC) (NCT03123653)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top